2020/07/23 by G. Adami, Giovanni Adami, A. Giollo +13
Biochemistry, Genetics and Molecular Biology · Medicine · #Bone Metabolism and Diseases #Bone health and osteoporosis research #Bone health and treatments
paper · pdf · doi:10.4081/reumatismo.2020.1267
crossref issued 2020/07/23 · crossref published 2020/07/23 · crossref published-online 2020/07/23 · openalex publication_date 2020/07/23 · crossref created 2020/07/28 · crossref deposited 2020/07/28 · openalex created_date 2025/10/10 · crossref indexed 2026/08/03 · openalex updated_date 2026/08/03
In this retrospective study, we intended to investigate the baseline fracture risk profile in patients who started treatment with different anti-osteoporotic medications. We analyzed retrospectively the fracture risk calculated with DeFRA, a validated FRAX derived tool, in women who started an anti-osteoporotic treatment from 2010 to 2017. We analyzed baseline data of 12,024 post-menopausal women aged over 50 years. Teriparatide initiators had a baseline 10-year risk of major osteoporotic fracture of 82.1% with a Standard Deviation (SD) of 66.5%. Denosumab initiators and zoledronic acid initiators had a greater 10-year baseline risk of fracture (54.3%, SD 46.5% and 47.0%, SD 42.0 respectively) than patients initiated on alendronate (24.9%, SD 34.6%) and patients initiated on risedronate (23.9%, SD 24.1%). Using DeFRA, a FRAX™ derived tool, we showed significantly different fracture risk profiles in women who were started on various therapeutic agents for the treatment of osteoporosis in routine clinical practice.